Drug eluting balloons are increasingly being used for percutaneous coronary interventions (PCI) as an alternative to bare metal and drug eluting stents. Drug eluting balloons are inflatable angioplasty balloons coated with an antiproliferative drug, which is slowly released at the treatment site during coronary angioplasty to prevent restenosis. They provide advantages such as reduced risk of late stent thrombosis and a lower rate of restenosis. They also avoid overstretching and damage to arterial walls caused by stents.

The global Drug Eluting Balloon Market is estimated to be valued at US$ 667.78 Mn in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The primary trend fueling the growth of the drug eluting balloon market size is the increasing adoption of drug eluting balloons over drug eluting stents during PCI procedures. Drug eluting balloons are associated with lower risks of restenosis as compared to plain old balloon angioplasty and avoid drawbacks associated with stents such as late stent thrombosis. Therefore, major medical device companies have increased their focus on developing advanced drug eluting balloons. This is leading to the launch of innovative drug eluting balloon products with enhanced drug coatings and delivery mechanisms.

Segment Analysis

The global drug eluting balloon market is dominated by the coronary artery disease segment. Coronary artery disease represents the majority share in the indication segment as it is more prevalent than peripheral artery disease. Patients with coronary artery disease often receive drug eluting balloon treatment to prevent restenosis post angioplasty. The growing geriatric population which is more susceptible to cardiovascular conditions also contributes to the large share of this segment.

Key Takeaways

The global Drug Eluting Balloon Market is estimated to be valued at US$ 667.78 Mn in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023 to 2030.

Regional analysis

The drug eluting balloon market in North America is expected to grow at a high rate during the forecast period. This is due to the advanced healthcare infrastructure and rising prevalence of cardiovascular diseases in the region. Additionally, strong presence of leading market players in countries like the US is supplementing market growth. Europe represented a sizable share of the global market attributed to growing awareness about advanced treatment methods and supportive healthcare reimbursement policies of regional governments.

Key players related content

Key players operating in the drug eluting balloon market are Cato Manufacturing Ltd, Culver Props, Inc., Delta Electronics, Inc., Dowty Circuits Limited, Hartzell Propeller, Inc., McCauley Propeller Systems, Inc., Sensenich Propeller Service, Inc., and others. These players are focusing on new product launches and geographical expansion to garner higher market share. For instance, Boston Scientific Corporation gained FDA approval to market its Eluvia drug-coated balloon which delivers the anti-restenotic drug paclitaxel.

Get more insights on this topic: https://www.newsstatix.com/drug-eluting-balloon-market-share-and-opportunity-analysis-2023-2030/